Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.4.0.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Condensed Consolidated Statements Of Operations    
Product revenue $ 2,088,178 $ 1,484,217
License and other revenue 35,708 18,889
Total Revenues 2,123,886 1,503,106
OPERATING EXPENSES    
Cost of product revenue 1,266,421 909,629
Research and development 2,027,712 1,401,723
Plasma centers 1,280,419 1,048,094
General and administrative 1,707,870 1,345,997
TOTAL OPERATING EXPENSES 6,282,422 4,705,443
LOSS FROM OPERATIONS (4,158,536) (3,202,337)
OTHER INCOME (EXPENSE):    
Interest income 13,508 4,982
Interest expense (467,441) (476,040)
Change in fair value of stock warrants 0 67,860
OTHER EXPENSE, NET (453,933) (403,198)
NET LOSS $ (4,612,469) $ (3,605,535)
NET LOSS PER COMMON SHARE - Basic and Diluted $ (0.43) $ (0.37)
WEIGHTED AVERAGE SHARES OUTSTANDING, Basic and Diluted 10,710,587 9,855,323